Activities and ultrastructural effects of antifungal combinations against simulated Candida endocardial vegetations

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2367-2376

  Pai, Manjunath P ^a   Samples, Marie L ^a   Mercier, Renee Claude ^a   Spilde, Michael N ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCYTOSINE; MICAFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; ENDOCARDITIS; FIBRIN CLOT; HUMAN; IN VITRO SELECTION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; ECHINOCANDINS; ENDOCARDITIS; FLUCYTOSINE; HUMANS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; MODELS, BIOLOGICAL; PYRIMIDINES; TRIAZOLES;

EID: 46249131625     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01557-07     Document Type: Article

References (33)

1. Al-Fattani, M. A., and L. J. Douglas. 2004. Penetration of Candida biofilms by antifungal agents. Antimicrob. Agents Chemother. 48:3291-3297.
2. Andes, D., and M. van Ogtrop. 2000. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob. Agents Chemother. 44:938-942.
3. Bachmann, S. P., K. VandeWalle, G. Ramage, T. F. Patterson, B. L. Wickes, J. R. Graybill, and J. L. Lopez-Ribot. 2002. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46:3591-3596.
4. Baddour, L. M., W. R. Wilson, A. S. Bayer, V. G. Fowler, Jr., A. F. Bolger, M. E. Levison, P. Ferrieri, M. A. Gerber, L. Y. Tani, M. H. Gewitz, D. C. Tong, J. M. Steckelberg, R. S. Baltimore, S. T. Shulman, J. C. Burns, D. A. Falace, J. W. Newburger, T. J. Pallasch, M. Takahashi, K. A. Taubert, et al. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation 111:e394-e434.
5. Bonow, R. O., B. A. Carabello, C. Kanu, A. C. de Leon, Jr., D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, R. A. O'Rourke, C. M. Otto, P. M. Shah, J. S. Shanewise, S. C. Smith, Jr., A. K. Jacobs, C. D. Adams, J. L. Anderson, E. M. Antman, D. P. Faxon, V. Fuster, J. L. Halperin, L. F. Hiratzka, S. A. Hunt, B. W. Lytle, R. Nishimura, R. L. Page, B. Riegel, et al. 2006. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Circulation 114:e84-e231.
6. Chemlal, K., L. Saint-Julien, V. Joly, R. Farinotti, N. Seta, P. Yeni, and C. Carbon. 1996. Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits. Antimicrob. Agents Chemother. 40:263-266.
7. Choi, H. W., J. H. Shin, S. I. Jung, K. H. Park, D. Cho, S. J. Kee, M. G. Shin, S. P. Suh, and D. W. Ryang. 2007. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob. Agents Chemother. 51:1520-1523.
8. Cutler, R. E., A. D. Blair, and M. R. Kelly. 1978. Flucytosine kinetics in subjects with normal and impaired renal function. Clin. Pharmacol. Ther. 24:333-342.
9. d'Enfert, C. 2006. Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr. Drug Targets 7:465-470.
10. Ellis, M. E., H. Al-Ahdely, A. Sandridge, W. Greer, and W. Ventura. 2001. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin. Infect. Dis. 32:50-62.
11. Flecknell, P. 2002. Replacement, reduction and refinement. ALTEX 19:73-78.
12. Garzoni, C., V. A. Nobre, and J. Garbino. 2007. Candida parapsilosis endocarditis: a comparative review of the literature. Eur. J. Clin. Microbiol. Infect. Dis. 26:915-926.
13. Kuhn, D. M., T. George, J. Chandra, P. K. Mukherjee, and M. A. Ghannoum. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780.
14. Louie, A., P. Kaw, P. Banerjee, W. Liu, G. Chen, and M. H. Miller. 2001. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob. Agents Chemother. 45:485-494.
15. Marrie, T. J., J. H. Cooper, and J. W. Costerton. 1984. Ultrastructure of Candida parapsilosis endocarditis. Infect. Immun. 45:390-398.
16. Martinez, M., and D. A. Stevens. 2006. Bioassay for azoles in presence of caspofungin (CF), and vice versa, p. M-1578. 46th Annu. Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
17. McFarland, M. M., E. M. Scott, and A. Li Wan Po. 1994. Time-survival studies for quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 38:1271-1276.
18. Meletiadis, J., P. E. Verweij, D. T. TeDorsthorst, J. F. Meis, and J. W. Mouton. 2005. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med. Mycol. 43:133-152.
19. Mercier, R. C., R. M. Dietz, J. L. Mazzola, A. S. Bayer, and M. R. Yeaman. 2004. Beneficial influence of platelets on antibiotic efficacy in an in vitro model of Staphylococcus aureus-induced endocarditis. Antimicrob. Agents Chemother. 48:2551-2557.
20. Moudgal, V., T. Little, D. Boikov, and J. A. Vazquez. 2005. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49:767-769.
21. Mukherjee, P. K., and J. Chandra. 2004. Candida biofilm resistance. Drug Resist. Updat. 7:301-309.
22. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A2, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
23. Norice, C. T., F. J. Smith, Jr., N. Solis, S. G. Filler, and A. P. Mitchell. 2007. Requirement for Candida albicans Sun41 in biofilm formation and virulence. Eukaryot. Cell 6:2046-2055.
24. Pai, M. P., R. M. Dietz, A. L. Jones, and R. C. Mercier. 2003. Pharmacodynamic evaluation of once-daily flucytosine and twice-daily voriconazole in an in vitro model of Candida albicans infective endocarditis, abstr. M-1249. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
25. Pai, M. P., A. L. Jones, and C. K. Mullen. 2007. Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method. Diagn. Microbiol. Infect. Dis. 58:129-132.
26. Pai, M. P., M. L. Samples, and R. C. Mercier. 2007. Candida albicans biofilm activity of flucytosine, liposomal amphotericin B, and micafungin in an in vitro pharmacodynamic model of simulated endocardial vegetations, p. M-1859. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
27. Pappas, P. G. 2006. Invasive candidiasis. Infect. Dis. Clin. N. Am. 20:485-506
28. Perea, S., G. J. Pennick, A. Modak, A. W. Fothergill, D. A. Sutton, D. J. Sheehan, and M. G. Rinaldi. 2000. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob. Agents Chemother. 44:1209-1213.
29. Shadomy, S. 1969. In vitro studies with 5-fluorocytosine. Appl. Microbiol. 17:871-877.
30. Tabata, K., M. Katashima, A. Kawamura, A. Kagayama, and S. Kohno. 2006. Pharmacokinetics-pharmacodynamics of micafungin in Japanese patients with deep-seated mycosis. Eur. J. Drug Metab. Pharmacokinet. 31: 123-128.
31. Theuretzbacher, U., F. Ihle, and H. Derendorf. 2006. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 45:649-663.
32. Wagner, C., W. Graninger, E. Presterl, and C. Joukhadar. 2006. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 78:161-177.
33. Witt, M. D., T. Imhoff, C. Li, and A. S. Bayer. 1993. Comparison of fluconazole and amphotericin B for treatment of experimental Candida endocarditis caused by non-C. albicans strains. Antimicrob. Agents Chemother. 37:2030-2032.